Biomarin Pharmaceutical Inc
Research Biomarin Pharmaceutical Inc (BMRN) on Bullrun: valuation model: 67.4% overvalued, market cap USD 10.61B, P/E 147.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBMRN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal67.4% overvalued
- Market capUSD 10.61B
- P/E147.7
- Financial periodQ2 2026
- RevenueUSD 989.71M
- Net incomeUSD 44.76M
- Free cash flowUSD 133.86M
- Gross margin79.5%
Valuation Snapshot
Bullrun's latest valuation model marks Biomarin Pharmaceutical Inc as 67.4% overvalued; latest market cap is USD 10.61B; P/E is 147.7.
Peer valuation comparison
Latest P/E is 147.75x versus a Healthcare sector median of 24.61x (500.4% above).
Latest P/E is 147.75x versus a United States median of 23.85x (519.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.22B | USD 348.90M | USD 724.96M | 77.7% | 1.8 | USD 1.31B | USD 597.18M | USD 6.09B |
| FY2024 | USD 2.85B | USD 426.90M | USD 487.42M | 79.7% | 2.21 | USD 942.84M | USD 602.71M | USD 5.66B |
| FY2023 | USD 2.42B | USD 167.60M | USD 62.57M | 78.0% | 0.87 | USD 755.13M | USD 1.10B | USD 4.95B |
| FY2022 | USD 2.10B | USD 141.60M | USD 54.94M | 76.0% | 0.75 | USD 724.53M | USD 1.09B | USD 4.60B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 10.61B | 147.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 11.43B | 33.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 12.54B | 29.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 18.16B | 126.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 19.23B | 246.4 | n/a | n/a |
| 2021 | 2021-12-31 | USD 16.25B | n/a | n/a | n/a |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder;
ETFs that hold Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Global X Genomics & Biotechnology UCITS ETF USD Acc | 3.58% | 0.50% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Biomarin Pharmaceutical Inc overvalued or undervalued?
Bullrun's valuation model currently marks Biomarin Pharmaceutical Inc as 67.4% overvalued.
What is Biomarin Pharmaceutical Inc's market cap?
Biomarin Pharmaceutical Inc's market capitalization is USD 10.61B.
What is Biomarin Pharmaceutical Inc's P/E ratio?
Biomarin Pharmaceutical Inc's price-to-earnings (P/E) ratio is 147.7.
What does Biomarin Pharmaceutical Inc do?
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.